LianBio (LIAN): Price and Financial Metrics
LIAN Price/Volume Stats
Current price | $0.32 | 52-week high | $4.99 |
Prev. close | $0.35 | 52-week low | $0.27 |
Day low | $0.28 | Volume | 2,485,000 |
Day high | $0.35 | Avg. volume | 1,037,083 |
50-day MA | $4.30 | Dividend yield | N/A |
200-day MA | $3.08 | Market Cap | 34.47M |
LIAN Stock Price Chart Interactive Chart >
LianBio (LIAN) Company Bio
Lianbio operates in the healthcare industry focusing on pharmaceutical business. The company is based in Camana Bay, Cayman Islands.
Latest LIAN News From Around the Web
Below are the latest news stories about LIANBIO that investors may wish to consider to help them evaluate LIAN as an investment opportunity.
LianBio Enters into Agreement Assigning its Rights for NBTXR3 in China and Other Asian MarketsSHANGHAI, China and PRINCETON, N.J., Dec. 26, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that the company has entered into an agreement with Janssen Pharmaceutica NV (“Janssen”), a Johnson & Johnson company, whereby Lian has assigned to Janssen LianBio’s exclusive rights to develop and commercialize NBTXR3, an investigational, potential first-in-class radio |
LianBio Announces Departure of Chief Financial OfficerSHANGHAI, China and PRINCETON, N.J., Dec. 20, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yi Larson, Chief Financial Officer, has resigned from LianBio to pursue other opportunities, effective December 19, 2023. In connection with her departure, the LianBio Board of Directors has appointed Ehong (Maggie) Gu, current VP, Head of Global Finance, as Interi |
LianBio Announces Departure of Chief Executive OfficerSHANGHAI, China and PRINCETON, N.J., Dec. 19, 2023 (GLOBE NEWSWIRE) -- LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that Yizhe Wang, Ph.D., Chief Executive Officer has resigned from LianBio to pursue other opportunities. In connection with his departure, the LianBio Board of Directors has appointed Adam Stone, Chief Investment Officer of Perceptive Advisors and member of the LianBio |
LianBio’s Board of Directors Unanimously Determines not to Pursue Unsolicited Proposal from Concentra BiosciencesSHANGHAI, China and PRINCETON, N.J., Dec. 06, 2023 (GLOBE NEWSWIRE) -- LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today announced that its Board of Directors (the “Board”) unanimously determined not to pursue the unsolicited proposal from Concentra Biosciences, LLC to acquire 100% of the equity of LianBio for $4.30 per share in cash, plus a contingent value right representing the right to receive |
LianBio Confirms Receipt of Unsolicited Proposal from Concentra BiosciencesSHANGHAI, China and PRINCETON, N.J., Dec. 01, 2023 (GLOBE NEWSWIRE) -- The Board of Directors (the “Board”) of LianBio (NASDAQ: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today confirmed that Concentra Biosciences, LLC (“Concentra”), of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal (the “Proposal”) to acquire 100% of the equity of LianBio. Accordin |
LIAN Price Returns
1-mo | -93.36% |
3-mo | -92.84% |
6-mo | -78.52% |
1-year | -81.71% |
3-year | N/A |
5-year | N/A |
YTD | -92.84% |
2023 | 172.56% |
2022 | -73.38% |
2021 | N/A |
2020 | N/A |
2019 | N/A |
Loading social stream, please wait...